All In Biotech

Drug Trial Radar · NCT02766608

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD

Last checked: Nov 19, 2026Latest source record: Sep 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,389 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,389

Actual

Start

May 31, 2016

Primary completion

Dec 1, 2017

Study completion Dec 1, 2017

Sponsor

Lead sponsor
Pearl Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg) administered BID.

Conditions

  • Chronic Obstructive Pulmonary Disorder

Interventions

  • BFF MDI 320/9.6 μgDrug

    Blinded Treatment

  • BFF MDI 160/9.6 μgDrug

    Blinded Treatment

  • FF MDI 9.6 μgDrug

    Blinded Treatment

  • BD MDI 320 μgDrug

    Blinded Treatment

  • Symbicort® TBH 400/12 μg BIDDrug

    Open Label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI)Time frame: at Week 24
  2. Change From Baseline in FEV1 AUC0-4 (BFF MDI vs BD MDI)Time frame: at Week 24

Locations

259 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Athens, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Dothan, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Anaheim, California

  • Research Site

    Gold River, California

  • Research Site

    Palm Springs, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    Boulder, Colorado

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Littleton, Colorado

  • Research Site

    Hamden, Connecticut

  • Research Site

    Clearwater, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    DeLand, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Panama City, Florida

  • Research Site

    Port Orange, Florida

  • Research Site

    Port Orange, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Blue Ridge, Georgia

  • Research Site

    Meridian, Idaho

  • Research Site

    Towson, Maryland

  • Research Site

    Westminster, Maryland

  • Research Site

    North Dartmouth, Massachusetts

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    Edina, Minnesota

  • Research Site

    Fridley, Minnesota

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Woodbury, Minnesota

  • Research Site

    Saint Charles, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Henderson, Nevada

Showing 40 of 259 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.